Vivanta Tablet 97 mg + 103 mg contains a higher-strength fixed-dose combination of Sacubitril and Valsartan, used for the long-term management of chronic heart failure with reduced ejection fraction (HFrEF). This strength is typically prescribed for patients who have been gradually titrated from lower doses and can tolerate higher therapeutic levels. Vivanta Tablet belongs to the class of angiotensin receptor–neprilysin inhibitors (ARNIs) and is proven to improve survival, reduce hospitalization rates, and enhance quality of life in heart failure patients.

Mechanism of Action

Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides. Inhibition of this enzyme increases beneficial peptides that promote vasodilation, sodium excretion, and reduced cardiac workload. Valsartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and fluid retention by blocking the angiotensin II receptor. Together, these complementary actions reduce cardiac stress, improve hemodynamic balance, and slow disease progression in heart failure.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Vivanta Tablet 97 mg + 103 mg is indicated for:

• Treatment of chronic heart failure with reduced ejection fraction

• Patients who have tolerated lower doses and require optimal therapeutic dosing

• Reduction of cardiovascular mortality and heart failure–related hospitalizations

• Use as a replacement for ACE inhibitors or other ARBs, under physician supervision

Dosage and Administration

The dosage of Vivanta Tablet should be determined by the treating physician based on the patient’s clinical status and treatment history. It is usually taken twice daily, with or without food. Tablets should be swallowed whole with water. Regular monitoring of blood pressure, kidney function, and serum potassium is essential, especially during dose escalation.

Benefits

• Provides optimal and sustained improvement in heart failure outcomes

• Significantly reduces the risk of hospitalization due to worsening heart failure

• Lowers the risk of cardiovascular death

• Improves symptoms, exercise tolerance, and overall quality of life

• Fixed-dose combination simplifies long-term treatment

Possible Side Effects

Vivanta Tablet is generally well tolerated, but some patients may experience:

• Low blood pressure (hypotension) or dizziness

• Elevated potassium levels

• Changes in kidney function

• Fatigue or headache

Rare but serious reactions such as angioedema require immediate medical attention.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Do not use with ACE inhibitors; a washout period is mandatory

• Use with caution in patients with renal impairment or low baseline blood pressure

• Contraindicated during pregnancy due to fetal risk

• Breastfeeding should be discussed with a healthcare provider

• Close medical supervision is required during maintenance therapy

Drug Interactions

Vivanta Tablet may interact with potassium supplements, potassium-sparing diuretics, NSAIDs, lithium, and other antihypertensive medicines. Patients should inform their physician of all medications they are taking before and during treatment.

Storage

Store Vivanta Tablet 97 mg + 103 mg in a cool, dry place away from direct sunlight. Keep out of reach of children.

Conclusion

Vivanta Tablet 97 mg + 103 mg (Sacubitril + Valsartan) represents the optimal maintenance dose for many patients with chronic heart failure with reduced ejection fraction. When used consistently under medical supervision, it significantly improves survival, reduces hospitalizations, and supports better long-term cardiovascular health.